If you have been reading about vaccine adjuvant and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The analysis of the debris at the 10-megaton Ivy Mike nuclear test was a part of long-term project. One of the goals was studying the efficiency of production of transuranic elements in high-power nuclear explosions. The motive for these experiments was that synthesis of such elements from uranium requires multiple neutron capture. The probability of such events increases with the neutron flux, and nuclear explosions are the most powerful man-made neutron sources, providing densities of the order 1023 neutrons/cm2 within a microsecond, or about 1029 neutrons/(cm2·s). In comparison, the flux of HFIR is 5×1015 neutrons/(cm2·s). A dedicated laboratory was set up right at Enewetak Atoll for preliminary analysis of debris, as some isotopes could have decayed by the time the debris samples reached the mainland U.S. The laboratory was receiving samples for analysis as soon as possible, from airplanes equipped with paper filters which flew over the atoll after the tests. Whereas it was hoped to discover new chemical elements heavier than fermium, none of these were found even after a series of megaton explosions conducted between 1954 and 1956 at the atoll. The atmospheric results were supplemented by the underground test data accumulated in the 1960s at the Nevada Test Site, as it was hoped that powerful explosions in a confined space might give improved yields and heavier isotopes.
== Connection to nitrogen storage in Cyanobacteria == Cyanophycin is highly resistant to degradation by all conventional proteases, and the only enzyme known to be capable of hydrolyzing it is cyanophycinase. Cyanophycin is a non-ribosomally synthesized peptidyl polymer that is used for nitrogen storage by cyanobacteria and other select eubacteria. Approximately 90% of cyanobacteria are diazotrophic, meaning that they can grow without an external source of fixed nitrogen. Diazotrophic growth was severely impaired in bacteria with a mutated cyanophycinase gene, indicating that the inability to degrade cyanophycin is detrimental for the diazotrophic growth of the cyanobacterium, due to an excess of nitrogen storage.
By 1936, the pool of missing elements from hydrogen to uranium had shrunk to four: elements 43, 61, 85, and 87 remained missing. Element 43 eventually became the first element to be synthesized artificially via nuclear reactions rather than discovered in nature. It was discovered in 1937 by Italian chemists Emilio Segrè and Carlo Perrier, who named their discovery technetium, after the Greek word for "artificial". Elements 61 (promethium) and 85 (astatine) were likewise produced artificially in 1945 and 1940 respectively; element 87 (francium) became the last element to be discovered in nature, by French chemist Marguerite Perey in 1939. The elements beyond uranium were likewise discovered artificially, starting with Edwin McMillan and Philip Abelson's 1940 discovery of neptunium (via bombardment of uranium with neutrons). Glenn T. Seaborg and his team at the Lawrence Berkeley National Laboratory (LBNL) continued discovering transuranium elements, starting with plutonium in 1941, and discovered that contrary to previous thinking, the elements from actinium onwards were congeners of the lanthanides rather than transition metals. Bassett (1892), Werner (1905), and the French engineer Charles Janet (1928) had previously suggested this, but their ideas did not then receive general acceptance. Seaborg thus called them the actinides. Elements up to 101 (named mendelevium in honour of Mendeleev) were synthesized up to 1955, either through neutron or alpha-particle irradiation, or in nuclear explosions in the cases of 99 (einsteinium) and 100 (fermium).
A text known as The Ritual of Embalming does describe some of the practical logistics of embalming; however, there are only two known copies and each is incomplete. With regards to mummification shown in images, there are apparently also very few. The tomb of Tjay, designated TT23, is one of only two known which show the wrapping of a mummy (Riggs 2014). Another text that describes the processes being used in the latter periods is Herodotus' Histories. Written in Book 2 of the Histories is one of the most detailed descriptions of the Egyptian mummification process, including the mention of using natron in order to dehydrate corpses for preservation. However, these descriptions are short and fairly vague, leaving scholars to infer the majority of the techniques that were used by studying mummies that have been unearthed. By utilizing current advancements in technology, scientists have been able to uncover a plethora of new information about the techniques used in mummification. A series of CT scans performed on a 2,400-year-old mummy in 2008 revealed a tool that was left inside the cranial cavity of the skull. The tool was a rod, made of an organic material, that was used to break apart the brain to allow it to drain out of the nose. This discovery helped to dispel the claim within Herodotus' works that the rod had been a hook made of iron. Earlier experimentation in 1994 by researchers Bob Brier and Ronald Wade supported these findings.
Sources: en.wikipedia.org
Ribosome profiling, or Ribo-Seq (also named ribosome footprinting), is an adaptation of a technique developed by Joan Steitz and Marilyn Kozak almost 50 years ago that Nicholas Ingolia and Jonathan Weissman adapted to work with next generation sequencing that uses specialized messenger RNA (mRNA) sequencing to determine which mRNAs are being actively translated. A related technique that can also be used to determine which mRNAs are being actively translated is the Translating Ribosome Affinity Purification (TRAP) methodology, which was developed by Nathaniel Heintz at Rockefeller University (in collaboration with Paul Greengard and Myriam Heiman). TRAP does not involve ribosome footprinting but provides cell type-specific information.
Seaborg was notified and the team left to sleep. Additional analysis and further experimentation showed the produced mendelevium isotope to have the expected mass of 256 and decay by electron capture to fermium-256 (half-life 157.6 minutes), the source of the observed fission.
Consultant Urologist, South Tyneside and Sunderland NHS Foundation Trust. For services to the NHS. Dr. Benjamin Marc Ellis. For services to Healthcare, to Equality and to the Jewish Community. Audley Horace English. Co-Founder, Society of Black Architects. For services to Architecture and Sustainability. Professor Stephen James Weston Evans. Emeritus Professor of Pharmacoepidemiology, London School of Hygiene and Tropical Medicine. For services to the Safety of Medicines. Stephen Wynne Evans. Founder, Belief. For voluntary and charitable services in North Wales. Helen Adesuwa Imatitkua Fadipe. Founder and Chair, BAME Planners Network. For services to Town Planning. Paul Fairweather. Trustee, Breakthrough Ltd. For services to Disabled People and to the LGBT Community in the North West. Catherine Susan, Baroness Fall. Lately Non Executive Director, Cultural Recovery Board. For services to Culture. Rhiane Estelle Fatinikun. Founder, Black Girls Hike. For services to Nature and to Diversity. Julie Patricia Felix. For services to Dance Education. James St John Fenny. Head of Office, Public Defender Service and Transplant Surgery Ambassador. For services to Criminal Justice and to Organ Donor Awareness. Dr. Julia Helen Fentem. Executive Vice President, Safety, Environmental and Regulatory Science, Unilever. For services to Human Health and Animal Welfare. Jacqueline Ferguson. President, London College of Dance Network and Volunteer, Healthwatch (Kensington and Chelsea). For services to the community in London. Lucy Catherine Ferguson. Founder and Director, Mediorite.
=== Laboratory Analysers === Automated analysers, by the association of robotics and spectrophotometry, have allowed these last decades better reproducibility of the results, in particular in medical biochemistry and hematology. Efficiency and productivity can be enhanced by automating the pre-analytical processing, including barcode reading, sorting, centrifuging, and aliquoting specimens. The analysers must undergo daily controls prior to performing patient testing. Analysers must also undergo daily, weekly and monthly maintenance. Quality management involves reviewing quality control trends to detect emerging problems in instrument calibration, correlating results between instruments that perform similar testing, and running standardized samples to prove linearity and precision. Some laboratory processes involve automated analysis combined with manual review by technologists. For example, when hematology analysers flag samples as abnormal, automated white blood cell differential counts may be superseded by manual differential counts using stained slides read at the microscope or scanned by digital imaging software. Laboratory technologists may flag abnormal samples for pathologist review. The pathologist may recommend additional testing, such as flow cytometry to identify lymphoma or leukemia cells, or cytology to characterize solid tumor cells.
=== Processing === The final peptide is often modified, e.g., by glycosylation, acylation, halogenation, or hydroxylation. The responsible enzymes are usually associated to the synthetase complex and their genes are organized in the same operons or gene clusters.
Sources: en.wikipedia.org
The pelvis was a large structure. Its upper bone, the ilium, was both very long and high, providing an extensive attachment area for hindlimb muscles. The front pubic bone ended in an enormous pubic boot, longer than the entire shaft of the element. The rear ischium was slender and straight, pointing obliquely to behind and below. In contrast to the arms, the hindlimbs were among the longest in proportion to body size of any theropod. In the foot, the metatarsus was "arctometatarsalian", meaning that the part of the third metatarsal near the ankle was pinched. The third metatarsal was also exceptionally sinuous. Compensating for the immense bulk of the animal, many bones throughout the skeleton were hollowed, reducing its weight without significant loss of strength.
=== On multi drug resistant cancer cells === Poloxamers have been shown to preferentially target cancer cells, due to differences in the membrane of these cells when compared to noncancer cells. Poloxamers have also been shown to inhibit MDR proteins and other drug efflux transporters on the surface of cancer cells; the MDR proteins are responsible for the efflux of drugs from the cells and hence increase the susceptibility of cancer cells to chemotherapeutic agents such as doxorubicin. Another effect of the polymers upon cancer cells is the inhibition of the production of ATP in multi-drug resistant (MDR) cancer cells. The polymers seem to inhibit respiratory proteins I and IV, and the effect on respiration seems to be selective for MDR cancer cells, which may be explained by the difference in fuel sources between MDR and sensitive cells (fatty acids and glucose respectively). The poloxamers have also been shown to enhance proto-apoptotic signaling, decrease anti-apoptoic defense in MDR cells, inhibit the glutathione/glutathione S-transferase detoxification system, induce the release of cytochrome C, increase reactive oxygen species in the cytoplasm, and abolish drug sequestering within cytoplasmic vesicles.
Around 1500 BCE a tribe called the Oenotri ("vine-cultivators"), settled in the region. Ancient sources state they were Greeks who were led to the region by their king, Oenotrus. However it is more likely they were an ancient Italic people who spoke an Italic language. During the eighth and seventh centuries BCE, Greeks founded many settlements on the coast of southern Italy. In Calabria they founded Chone (Pallagorio), Cosentia (Cosenza), Clampetia (Amantea), Scyllaeum (Scilla), Sybaris (Sibari), Hipponion (Vibo Valentia), Epizephyrian Locris (Locri), Kaulon (Monasterace), Krimisa (Cirò Marina), Kroton (Crotone), Laüs (comune of Santa Maria del Cedro), Medma (Rosarno), Metauros (Gioia Tauro), Petelia (Strongoli), Rhégion (Reggio Calabria), Scylletium (Borgia), Temesa (Campora San Giovanni), Terina (Nocera Terinese), Pandosia (Acri) and Thurii, (Thurio, comune of Corigliano Calabro). In the year 744 BCE a group of Chalcidian settlers founded Rhegion (today Reggio Calabria) at the southern end of the peninsula. Soon after, other Chalcidans founded Zancle (current Messina) on the other side of the strait, securing their dominion over that arm of the sea. Later Chalcidian settlers from Rhegion and Zancle founded Metauros (Gioia Tauro) and divided the river of the same name (today Petrace) from the Italic city of the Tauri. In 710 BCE Ionian colonists founded Sybaris on the fertile plain of the same name at the mouth of the Crati.
In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA. In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue.
=== Category:EC 3.2 (act on sugars - glycosylases) === Category:EC 3.2.1 Amylase (EC 3.2.1.1) Sucrase (EC 3.2.1.10) Chitinase (EC 3.2.1.14) Lysozyme (EC 3.2.1.17) Maltase (EC 3.2.1.20) Lactase (EC 3.2.1.23) Beta-galactosidase (EC 3.2.1.23) Hyaluronidase (EC 3.2.1.35)
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.